eesohbel's version from 2015-08-08 19:04

Section 1

Question Answer
MOA of cyclosporinecalcineurin inhibitor. binds cyclophilin Prevents IL-2 transcription
Clinical use of cyclosporinetransplant rejection, prophylaxis, psoriasis, RA
A/E of cyclosporinenephrotoxic, gingival hyperplasia, hirsutism
MOA of tacrolimuscalcineurin inhibitor. Binds to FK-binding protein. Prevents IL-2 transcription.
Clinical use of tacrolimustransplant rejection. prophylaxis
A/E of tacrolimussimilar to cyclosporine, but no gingival hyperplasia and hirsutism. Increased risk of diabetes.
MOA of sirolimusmTOR inhibitor. binds to FKBP-12. Prevents response to IL-2.
Clinical use of sirolimus. Immunosuppression after kidney transplant in combination with cyclosporin and corticosteroids.
A/E sirolimushyperlipidemia, thrombocytopenia, leukopenia
MOA azathiopurineanti metabolite precursor of 6MP inhibits lymphocyte proliferation by blocking nucleotide synthesis
Clinical use of azathiopurinekidney transplant. autoimmune disorders
A/E azathiopurine active metabolite (mercaptopurine) is metabolized by XO--so increased effects with allopurinol
MOA of glucocorticoidsinhibits NF-kappaB. Suppresses T and B cell function.
Clinical use of glucocorticoidstransplant rejection and prophylaxis
A/E of glucocorticoidsiatrogenic cushing
MOA of thalidomideinhibits TNF alpha production
Clinical use of thalidomideHansen disease, multiple myeloma
A/E of thalidomidesevere hypoplasia of limbs of fetus if used during pregnancy
MOA of myclophenalateinhibits IMP. prevents lymphocyte proliferation.
clinical use of mycophenalatetransplant, lupus nephritis
A/E of mycophenalatelymphoma

Section 2

Question Answer
alemtuzumab targetCLL
alemtuzumab clinical use colorectal cancer, renal cell carcinoma
rituximab targetCD20
rituximab clinical useB cell non hodgkin lymphoma, CLL, RA, arthritis
trastuzumab targetHER2/NEU
trastuzumab clinical usebreast cancer
adalimumab targetsoluble TNF-alpha
clinical use of adalimumabIBD
target of natalizumab alpha 4 integrin
clinical use of natalizumabMS, Crohn's
abciximab targetplatelet glycoproteins IIb/IIIa
clinical use of abciximabantiplatelet agent
denosumab targetRANKL
denosumab clinical useosteoporosis. inhibits osteoclast maturation
omalizumab targetIgE
omalizumab clinical useallergic asthma
palivizumab targetRSV protein
palivizumab clinical targetRSV prophylaxis for high risk infants
ranibizumab clinical targetVEGF
ranibizumab clinical useneovascular age related macular degeneration
eculizumab clinical targetcomplement protein C5
eculizumab clinical usePNH

Recombinant cytokines

AgentClinical uses
Aldesleukin (interleukin-2)Renal cell carcinoma
metastatic melanoma
Epoetin alfa (erythropoietin)Anemias (esp in renal failure)
Filgrastim (granulocyte colony-stimulating factor)Recovery of bone marrow
Sargramostim (granulocyte-macrophage colony-stimulating factor)Recovery of bone marrow
a-interferonHep B & C
Kaposi's sarcoma
Malignant melanoma
gamma-interferonChronic granulomatous disease
Oprelvekin (interleukin-11)Thrombocytopenia

Recent badges